Monte Rosa Therapeutics(US:GLUE) Globenewswire·2025-09-15 11:00Core Insights - Monte Rosa Therapeutics has entered into an exclusive collaboration with Novartis to develop novel molecular glue degraders for immune-mediated diseases, marking the second agreement between the two companies [1][3][4] - The agreement is structured to accelerate the development of degraders targeting difficult-to-drug immune-mediated diseases, utilizing Monte Rosa's proprietary AI/ML-enabled QuEEN™ product engine [2][3] - Monte Rosa will receive an upfront payment of $120 million and has the potential to earn up to $5.7 billion in total deal value, including various milestone payments and tiered royalties on global net sales [4] Agreement Details - The collaboration allows Monte Rosa to leverage Novartis' development and commercialization capabilities, enhancing the financial position of Monte Rosa and enabling the advancement of its pipeline programs [3][4] - Monte Rosa's pipeline includes multiple undisclosed targets in Th1, Th2, and Th17-driven autoimmune conditions, with plans to provide updates on its cash position in the upcoming earnings report [5] Company Overview - Monte Rosa Therapeutics is focused on developing highly selective molecular glue degrader medicines for serious diseases, including oncology and autoimmune conditions [7] - The QuEEN™ discovery engine combines AI-guided chemistry and structural biology to design MGDs with unprecedented selectivity, positioning Monte Rosa as a leader in the MGD space [7]